Results for this period
Full year1 April 2025–31 March 2026ConsolidatedJapanese GAAPThe width of the band at each stage is based on revenue. The narrower it becomes toward the bottom, the smaller the proportion of revenue that remains as profit. The dotted outline is the full-year forecast and the band inside it is the result for this period. The progress rate is the result divided by the forecast.
塗りつぶした部分が自己資本比率です。総資産のうち、返済のいらない自前の資金がどれだけかを表します。The thin vertical line indicates the level at the end of the previous fiscal year.
Stacked from zero: upward is an increase in cash, downward a decrease (in ¥ million).The net change represented by the dotted line is the total of three items, calculated from figures provided by the company.
Revenue increased as new customer acquisition remained steady and price optimization initiatives progressed smoothly. Although depreciation and amortization increased following the start of operations at the new building, the increase in revenue from new customer acquisition and price optimization resulted in higher earnings. Other contributing factors included increased orders for store inspections and certification services in the food consulting business, steady demand for outsourced norovirus testing, increased replacement demand in the medical information systems business, and an increase in new cases acquired for SMO services.
No applicable matters
| Item | Details |
|---|---|
| Fiscal Period Classification | Full year |
| Accounting standards | Japanese GAAP |
| Consolidated / non-consolidated | Consolidated |
| Period Covered | 1 April 2025–31 March 2026 |
| Net Sales | ¥150,262 million (YoY +4.9%) |
| Operating profit | ¥10,421 million (YoY +11.3%) |
| Ordinary income | ¥11,014 million (YoY +10.5%) |
| Profit attributable to owners of the parent | ¥7,748 million (YoY +23.7%) |
| Net income per share | ¥203.54 |
| Operating Margin | 6.9 |
| Equity ratio | End of the current fiscal period 69.7 / End of previous period 70.7 |
| Total assets | ¥183,247 million |
| Net assets | ¥132,129 million |
| Cash flows from operating activities | ¥20,715 million |
| Cash flows from investing activities | ¥-7,689 million |
| Cash flows from financing activities | ¥-12,351 million |
| Cash and cash equivalents at end of period | ¥64,602 million |
| Full-year earnings forecast | Net Sales ¥155,000 million (YoY +3.2%) / Operating profit ¥10,500 million (YoY +0.8%) / Ordinary income ¥11,000 million (YoY -0.1%) / Net income ¥7,000 million (YoY -9.7%) |
| Annual Dividend Forecast | ¥125 → ¥125（0.0%） |
| Payout ratio | Fiscal year ending March 2026 61.4 / Forecast for the fiscal year ending March 2027 66.9 |
| Segment revenue | Testing Business ¥143,191 million (YoY +5.1%) |
| Depreciation and amortization | ¥9,121 million |
| Impairment loss | ¥372 million |
| Breakdown of extraordinary income (loss) | Extraordinary income Gain on sale of non-current assets ¥1,201 million, Other ¥161 million / Extraordinary loss Impairment Losses ¥372 million, Other ¥16 million |
| Disclosure regarding the going concern assumption | No applicable matters |
| Change in accounting policy | Changes due to revisions to standards No / Other changes No / Change in accounting estimate No / Restatement No |
| Changes in the scope of consolidation | New Number of companies 0 / Company name Not disclosed / Excluded Number of companies 1 / Company name 株式会社BMLライフサイエンス・ホールディングス |
| Material subsequent events | No applicable matters. |
| Availability of Supplementary Financial Results Materials | Yes |
| Availability of Financial Results Briefing | Whether applicable Yes / Subject person Not disclosed |
| Issued Shares at Period-End | 40,749,426 |
| Treasury Shares at Period-End | 3,265,827 |
| Factors Behind Changes in Business Performance | Revenue increased as new customer acquisition remained steady and price optimization initiatives progressed smoothly. Although depreciation and amortization increased following the start of operations at the new building, the increase in revenue from new customer acquisition and price optimization resulted in higher earnings. Other contributing factors included increased orders for store inspections and certification services in the food consulting business, steady demand for outsourced norovirus testing, increased replacement demand in the medical information systems business, and an increase in new cases acquired for SMO services. |
Items this document does not state (5)
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.Revenue increased due to steady new customer acquisition and the smooth progress of price optimization initiatives undertaken since the previous year. Depreciation and amortization increased following the start of operations at the new building of BML総合研究所, but the increase in revenue from new customer acquisition and price optimization resulted in higher earnings.